How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8638"
  ["article_id"]=>
  string(4) "8638"
  [1]=>
  string(72) "Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease"
  ["article_title"]=>
  string(72) "Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease"
  [2]=>
  string(150) "The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infec"
  ["short_description"]=>
  string(150) "The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infec"
  [3]=>
  string(595) "
The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio 
&#nl
The post Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(595) "
The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio 
&#nl
The post Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(124) "https://www.pharmaceutical-business-review.com/news/sanofi-translate-bio-to-develop-novel-mrna-vaccine-for-covid-19-disease/"
  ["blog_url"]=>
  string(124) "https://www.pharmaceutical-business-review.com/news/sanofi-translate-bio-to-develop-novel-mrna-vaccine-for-covid-19-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the devel

array(40) {
  [0]=>
  string(4) "8639"
  ["article_id"]=>
  string(4) "8639"
  [1]=>
  string(64) "EMA grants orphan drug designation to AlloVir’s Viralym-M"
  ["article_title"]=>
  string(64) "EMA grants orphan drug designation to AlloVir’s Viralym-M"
  [2]=>
  string(155) "Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of "
  ["short_description"]=>
  string(155) "Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of "
  [3]=>
  string(616) "
Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of serious viral diseases caused by six commonly occurring, devastating 
&#nl
The post EMA grants orphan drug designation to AlloVir’s Viralym-M appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(616) "
Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of serious viral diseases caused by six commonly occurring, devastating 
&#nl
The post EMA grants orphan drug designation to AlloVir’s Viralym-M appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(109) "https://www.pharmaceutical-business-review.com/news/ema-grants-orphan-drug-designation-to-allovirs-viralym-m/"
  ["blog_url"]=>
  string(109) "https://www.pharmaceutical-business-review.com/news/ema-grants-orphan-drug-designation-to-allovirs-viralym-m/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EMA grants orphan drug designation to AlloVir’s Viralym-M

Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being develope

array(40) {
  [0]=>
  string(4) "8640"
  ["article_id"]=>
  string(4) "8640"
  [1]=>
  string(107) "FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis"
  ["article_title"]=>
  string(107) "FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis"
  [2]=>
  string(150) "ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initia"
  ["short_description"]=>
  string(150) "ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initia"
  [3]=>
  string(673) "
ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based 
&#nl
The post FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(673) "
ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based 
&#nl
The post FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(152) "https://www.pharmaceutical-business-review.com/news/fda-approves-bristol-myers-squibbs-zeposia-oral-treatment-for-relapsing-forms-of-multiple-sclerosis/"
  ["blog_url"]=>
  string(152) "https://www.pharmaceutical-business-review.com/news/fda-approves-bristol-myers-squibbs-zeposia-oral-treatment-for-relapsing-forms-of-multiple-sclerosis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of m

ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator t

array(40) {
  [0]=>
  string(4) "8641"
  ["article_id"]=>
  string(4) "8641"
  [1]=>
  string(85) "Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease"
  ["article_title"]=>
  string(85) "Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease"
  [2]=>
  string(152) "Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux "
  ["short_description"]=>
  string(152) "Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux "
  [3]=>
  string(581) "
Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux are part of the consortium. The firms are working 
&#nl
The post Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(581) "
Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Sanofi, BD and bioMérieux are part of the consortium. The firms are working 
&#nl
The post Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/novartis-bmgf-covid-19/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/novartis-bmgf-covid-19/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease

Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pf

array(40) {
  [0]=>
  string(4) "8642"
  ["article_id"]=>
  string(4) "8642"
  [1]=>
  string(197) "ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines"
  ["article_title"]=>
  string(197) "ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines"
  [2]=>
  string(150) "This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of tech"
  ["short_description"]=>
  string(150) "This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of tech"
  [3]=>
  string(835) "
This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of technology to support patients 
&#nl
The post ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(835) "
This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of technology to support patients 
&#nl
The post ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(242) "https://www.pharmaceutical-business-review.com/news/clinones-remote-clinical-trial-patient-management-technology-allows-pharmaceutical-companies-to-continue-clinical-research-efforts-amidst-covid-19-pandemic-in-accordance-with-fda-guidelines/"
  ["blog_url"]=>
  string(242) "https://www.pharmaceutical-business-review.com/news/clinones-remote-clinical-trial-patient-management-technology-allows-pharmaceutical-companies-to-continue-clinical-research-efforts-amidst-covid-19-pandemic-in-accordance-with-fda-guidelines/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ClinOne’s remote clinical trial patient management technology allows pharmaceutical

This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators 

array(40) {
  [0]=>
  string(4) "8643"
  ["article_id"]=>
  string(4) "8643"
  [1]=>
  string(82) "Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer"
  ["article_title"]=>
  string(82) "Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer"
  [2]=>
  string(150) "IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable "
  ["short_description"]=>
  string(150) "IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable "
  [3]=>
  string(583) "
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of 
&#nl
The post Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(583) "
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of 
&#nl
The post Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/infinity-ipi-549-urothelial-cancer/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/infinity-ipi-549-urothelial-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fa

array(40) {
  [0]=>
  string(4) "8644"
  ["article_id"]=>
  string(4) "8644"
  [1]=>
  string(94) "Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)"
  ["article_title"]=>
  string(94) "Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)"
  [2]=>
  string(154) "“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (hATTR) amyloidosis with polyneuropathy"
  ["short_description"]=>
  string(154) "“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (hATTR) amyloidosis with polyneuropathy"
  [3]=>
  string(660) "
“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (hATTR) amyloidosis with polyneuropathy in Turkey where we currently don’t have 
&#nl
The post Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(660) "
“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (hATTR) amyloidosis with polyneuropathy in Turkey where we currently don’t have 
&#nl
The post Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/alnylam-pharmaceuticals-and-gen-sign-distribution-agreement-in-turkey-for-onpattro-patisiran/"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/alnylam-pharmaceuticals-and-gen-sign-distribution-agreement-in-turkey-for-onpattro-patisiran/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:27"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisi

“Our partnership with Gen enables us to extend access to ONPATTRO to patients suffering from hereditary ATTR (h

array(40) {
  [0]=>
  string(4) "8897"
  ["article_id"]=>
  string(4) "8897"
  [1]=>
  string(106) "Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension"
  ["article_title"]=>
  string(106) "Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension"
  [2]=>
  string(154) "“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,"
  ["short_description"]=>
  string(154) "“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,"
  [3]=>
  string(678) "
“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,” said Habib Dable, President and 
&#nl
The post Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(678) "
“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,” said Habib Dable, President and 
&#nl
The post Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(159) "https://www.pharmaceutical-business-review.com/news/acceleron-receives-fda-breakthrough-therapy-designation-for-sotatercept-in-pulmonary-arterial-hypertension/"
  ["blog_url"]=>
  string(159) "https://www.pharmaceutical-business-review.com/news/acceleron-receives-fda-breakthrough-therapy-designation-for-sotatercept-in-pulmonary-arterial-hypertension/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arter

“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial

array(40) {
  [0]=>
  string(4) "8898"
  ["article_id"]=>
  string(4) "8898"
  [1]=>
  string(60) "OncoImmune receives FDA approval for COVID-19 clinical trial"
  ["article_title"]=>
  string(60) "OncoImmune receives FDA approval for COVID-19 clinical trial"
  [2]=>
  string(150) "A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg IV infusion) or placebo and"
  ["short_description"]=>
  string(150) "A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg IV infusion) or placebo and"
  [3]=>
  string(556) "
A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg IV infusion) or placebo and followed for 
&#nl
The post OncoImmune receives FDA approval for COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg IV infusion) or placebo and followed for 
&#nl
The post OncoImmune receives FDA approval for COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(113) "https://www.pharmaceutical-business-review.com/news/oncoimmune-receives-fda-approval-for-covid-19-clinical-trial/"
  ["blog_url"]=>
  string(113) "https://www.pharmaceutical-business-review.com/news/oncoimmune-receives-fda-approval-for-covid-19-clinical-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

OncoImmune receives FDA approval for COVID-19 clinical trial

A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (4

array(40) {
  [0]=>
  string(4) "8899"
  ["article_id"]=>
  string(4) "8899"
  [1]=>
  string(93) "FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic CRC"
  ["article_title"]=>
  string(93) "FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic CRC"
  [2]=>
  string(150) "Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, "
  ["short_description"]=>
  string(150) "Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, "
  [3]=>
  string(557) "
Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, which is claimed 
&#nl
The post FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic CRC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(557) "
Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, which is claimed 
&#nl
The post FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic CRC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/pfizer-braftovi-cetuximab/"
  ["blog_url"]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/pfizer-braftovi-cetuximab/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic

Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on

array(40) {
  [0]=>
  string(4) "8900"
  ["article_id"]=>
  string(4) "8900"
  [1]=>
  string(72) "Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1"
  ["article_title"]=>
  string(72) "Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1"
  [2]=>
  string(150) "In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. C"
  ["short_description"]=>
  string(150) "In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. C"
  [3]=>
  string(572) "
In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening 
&#nl
The post Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(572) "
In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening 
&#nl
The post Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/alnylam-lumasiran-ph1-approval/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/alnylam-lumasiran-ph1-approval/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1

In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) fo

array(40) {
  [0]=>
  string(4) "8901"
  ["article_id"]=>
  string(4) "8901"
  [1]=>
  string(54) "CROMSOURCE announces launch of COVID-19 clinical trial"
  ["article_title"]=>
  string(54) "CROMSOURCE announces launch of COVID-19 clinical trial"
  [2]=>
  string(150) "This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the Unit"
  ["short_description"]=>
  string(150) "This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the Unit"
  [3]=>
  string(552) "
This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States. “The 
&#nl
The post CROMSOURCE announces launch of COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(552) "
This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States. “The 
&#nl
The post CROMSOURCE announces launch of COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(107) "https://www.pharmaceutical-business-review.com/news/cromsource-announces-launch-of-covid-19-clinical-trial/"
  ["blog_url"]=>
  string(107) "https://www.pharmaceutical-business-review.com/news/cromsource-announces-launch-of-covid-19-clinical-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

CROMSOURCE announces launch of COVID-19 clinical trial

This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countr